A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily With Placebo in Patients With Non-Metastatic Prostate Cancer.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Survival
Throughout study period
No
Peter Iversen, MD
Principal Investigator
Department of Urology Rigshospitalet Copenhagen, Denmark
Denmark: Danish Dataprotection Agency
D6876C00025
NCT00672282
October 1995
August 2008
Name | Location |
---|